Innovative genetic tests for everyday life
Luminex Licensed Technologies Partners span a broad range of markets, company sizes and stages, and locations. The versatility of xMAP® Technology has supported the launch of thousands of multiplexed nucleic acid detection assays and immunoassays formatted into commercially available kits and testing services.
Gisela Aguirre, PhD, is CEO of Hakken Enterprise, based in the city of Cuernavaca, Mexico. The company aims to transform the lives of Mexicans by driving advances in science. Gisela speaks about how her team uses xMAP Technology.
Tell me about Hakken Enterprise and your role there.
Hakken Enterprise, a Mexican biotech company, is committed to transforming the Mexican health system by generating innovative and affordable genetic tests. We pursue diagnostic tools to improve patient care and the overall quality of life. My role is mainly to drive innovation by setting project goals and providing my coworkers with the tools needed to achieve these goals. We are opening the door to cutting-edge technologies for our country, so we are very proud of that.
What products/services do you offer?
Currently, we are developing two innovative diagnostic tools and are about to launch them this year. One is for HPV genotyping and simultaneously detecting the propensity for developing prostate cancer or cervical cancer. The other test is focused on identifying cancer-predisposing mutations: by taking a saliva sample from an individual, we can determine their predisposition to develop seven of the most common types of cancer. Both tests are precise, affordable, and very fast. Our focus is not to diagnose cancer but to prevent it. We can give access to physicians to create personalized monitoring plans — and in the case that someone develops cancer, physicians can select the best therapy based on their genetic profile.
How does xMAP Technology help?
xMAP Technology is a great advantage for us because we can test for up to 50 markers at a time. Compared with other platforms it is very fast, and the quantity of DNA required is very little. Since xMAP Technology works with a very low quantity of DNA, we are able to use noninvasive samples, such as saliva or urine samples, in which the concentration of DNA is very low compared with blood, for example. The sensitivity of this platform is even better than sequencing because we do not require a step for purification. The time and cost-effective results are a great advantage for us.
Resources
- Getting Started with xMAP® Technology [VIDEO]
- Browse 1,200+ Partner Kits with xMAP® Kit Finder [ONLINE TOOL]
- xMAP® Cookbook to Design Your Own Assays [DOWNLOAD]
Are you interested in developing, manufacturing, and commercializing a multiplexed assay on a platform that is efficient, flexible, and widely-adopted? Contact Luminex Business Development at http://info.luminexcorp.com/en-us/become-a-partner.
